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Abstract
Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving
clinical outcomes in all subtypes of breast cancer. Triple negative breast cancers (TN) are most likely to have tumors
with >50 % lymphocytic infiltrate, termed lymphocyte predominant breast cancer, and derive the greatest survival
benefit from each 10 % increase in TIL. The majority of HER2+ breast cancers have similar level of immune infiltrate
as TN breast cancer yet the presence of TILs has not shown the same survival benefit. For HER2+ breast cancers,
type 1 T-cells, either increased TBET+ tumor infiltration or increased type 1 HER2-specific CD4+ T-cells in the peripheral
blood, are associated with better outcomes. Hormone receptor positive HER2 negative tumors tend to have the least
immune infiltrate yet are the only breast cancer subtype to show worse prognosis with increased FOXP3 regulatory
T-cell infiltrate. Notably, all breast cancer subtypes have tumors with low, intermediate, or high TIL infiltrate. Tumors
with high TILs may also have increased PD-L1 expression which might be the reason that TN breast cancer seems to
demonstrate the most robust clinical response to immune checkpoint inhibitor therapy but further investigation is
needed. Tumors with intermediate or low levels of pre-treatment immune infiltrate, on the other hand, may benefit
from an intervention that may increase TIL, particularly type 1 T-cells. Examples of these interventions include specific
types of cytotoxic chemotherapy, radiation, or vaccine therapy. Therefore, the systematic evaluation of TIL and specific
populations of TIL may be able to both guide prognosis and the appropriate sequencing of therapies in breast cancer.
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Background
Infiltration of immune cells, particularly infiltration of
anti-tumor type 1 lymphocytes, has predicted improved
prognosis in many different tumor types including colon,
ovarian, lung and breast cancer [1–4]. Historically breast
cancer was not thought to be immunologically active,
particularly when compared to tumors such as melan-
oma. However recent evidence has emerged that tumor
infiltrating lymphocytes (TILs) present in breast cancer
prior to treatment can predict response to therapy and
improved prognosis [4, 5].
Not only does the amount of lymphocytic infiltration
but also the phenotype of that infiltrate determine clin-
ical outcome. Type 1 T-cells are associated with favor-
able prognosis. CD4+ T-helper 1 (Th1) cells facilitate
antigen presentation through cytokine secretion and
activation of antigen presenting cells. CD8+ cytotoxic
T-cells (CTL) are essential for tumor destruction [6].
On the other hand, type 2 CD4+ T-helper cells (Th2),
including Forkhead box P3 (FOXP3) CD4+ regulatory
T-cells, inhibit CTL function, support proliferation of
B-lymphocytes, and may promote an anti-inflammatory
immune response that could enhance tumor growth [7].
Lymphocyte levels in breast cancer and prognosis
The adaptive immune response to breast cancer can be
seen in infiltrating breast lesions as early as benign breast
atypia and increases in density as invasive malignancy
develops. In one retrospective study of 53 mastectomy
samples, increased B-cell and T-cell immune infiltrate
was identified in benign ductal hyperplasia, increased in
ductal carcinoma in situ (DCIS), and was found in the
greatest magnitude in invasive breast cancer [8]. In a
study of 27 DCIS patients, all tumors demonstrated
some level of TIL and 78 % of DCIS had >5 % infiltrate.
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High lymphocytic infiltrate was associated with young age
and triple negative (TN) DCIS, similar to invasive cancer,
with all TN DCIS (p = 0.0008) having programed death-
ligand 1 (PD-L1) expression [9]. The phenotype of the
T-cell response has also been shown to predict progno-
sis in DCIS. In a study of 62 DCIS samples, FOXP3+
infiltrate above the mean predicted decreased relapse
free survival (RFS) (HR 2.8; 95 % CI 0.99–7.99, p = 0.05)
[10]. Conversely, increased expression of a Th1 gene sig-
nature predicted improved survival in 31 patients with
DCIS [11]. Tumor lymphocytic infiltrate may be able to
be developed for use to stratify risk of recurrence and
need for aggressive therapies in DCIS, and immune ther-
apies may provide well-tolerated approaches to explore
for improved DCIS treatment [12].
In invasive breast cancer, the greatest clinical benefit
is seen in tumors with >50 % lymphocytic infiltrate
(lymphocyte predominant breast cancer (LPBC)). In pa-
tients with locally advanced breast cancer treated with
neoadjuvant chemotherapy, patients with LPBC had a
40 % pathologic complete response (pCR) (OR 1.38, p =
0.012 95 % CI 1.08–1.78) as compared to 7 % pCR in
patients with tumors that had no lymphocytic infiltrate
[4]. Increased CD8+ T-cells have also been shown to
predict improved clinical outcome, with higher intratu-
moral CD8+ T-cell infiltrate associated with improved
breast cancer specific survival (HR 0.55 95 % CI, 0.39
to 0.78 p = 0.001) in one large study of 1334 patients
[13]. This has not been replicated in other clinical studies
[14–16]. Infiltration of TBET+ cells (T-box transcription
factor TBX21, a marker of type 1 T-cells) can also predict
improved disease free survival (DFS) in all breast cancer
subtypes with breast cancer patients with tumors con-
taining < 30 TBET+ cells having decreased DFS as com-
pared to patients with tumors containing ≥30 TBET+
cells (RR 5.62 95 % CI 1.48–50.19 p = 0.0027 n = 617)
[17]. On the other hand, the presence of the Th2
marker FOXP3+ in the tumor has been associated with
worse prognosis. In an evaluation of over 200 breast
cancers, patients with tumors containing greater than
15 FOXP3+ cells had decreased RFS (p = 0.04 HR 1.58,
95 % CI 1.01 to 2.47) and overall survival (OS) (p = 0.07,
HR 1.62 95 % CI 0.96 to 2.74) [10]. Even when examining
all breast cancer subtypes together, the composition and
magnitude of the tumor immune infiltrate affects clinical
outcome and demonstrates that breast cancer is an im-
munogenic tumor. However the impact of TILs on clinical
outcome is most evident when the breast cancer subtypes
are evaluated separately.
In HER2+ and TN breast cancer, even incremental in-
creases in TILs both in and surrounding the tumor
have shown to predict both response to chemotherapy
and improved survival in patients [5, 18–20]. Further-
more, LPBC is more common in both TN and HER2+
breast cancers, with a median of 20 % TN tumors and
16 % HER2+ tumors having LPBC (Fig. 1a) [21]. One
study of 256 TN tumors demonstrated every 10 % in-
crease in TIL correlated with a 17 % decrease in the
risk of recurrence (p = 0.023, HR 0.83; 95 % CI 0.71–
0.98) and a 27 % decreased risk of death (p = 0.035, HR
0.73; 95 % CI 0.54–0.98) [5]. Similarly, for each 10 %
increase in stromal TIL there was 18 % increase in OS
(HR 0.82 95 % CI 0.69–0.96) in 112 HER2+ breast
cancer patients [20]. For both HER2+ and TN breast
cancer, while the best response has been seen in LPBC
that have the highest infiltrate, even small increases in
TIL lead to incremental increases in improved survival
and may suggest that even therapies that modestly in-
crease TIL can benefit clinical outcome in these subtypes.
Both TN and HER2+ patients have evidence of CD8+
T-cell infiltrate with approximately 60 % of tumors
containing CD8+ T-cells (Fig. 1b) [21]. CD8+ infiltrate
has only been shown to predict a survival benefit in TN
breast cancer; improved breast cancer specific survival
was seen with any intratumoral CD8+ infiltrate (p = 0.001,
HR 0.35; 95 % CI 0.23 to 0.54 n = 927) (Table 1) [15].
While intratumoral CD8+ T-cells do not predict improved
clinical outcome in HER2+ breast cancer, TBET+ tumor
infiltrate predicted improved RFS (p = 0.04 HR 4.76,
95 % CI 1.07 to 20) in 102 HER2 tumors treated with
trastuzumab [22]. For HER2+ breast cancer, the effect
of CD8+ tumor infiltrate may require hormone positive
HER2+ tumors to be evaluated separately from hormone
negative HER2+ tumors. The only study that stratified
HER2+ tumors by hormone receptor status found that
CD8+ tumor infiltrate was associated with RFS (p = 0.041)
(p = 0.064, HR 0.75 % CI 0.51–1.11 n = 227) in hormone
receptor negative HER2+ breast cancer but not hormone
receptor positive HER2+ breast cancer [15]. These data
suggest that the immune infiltrate in HER2+ breast cancer
may be more influenced by hormone receptor status
rather than HER2 protein overexpression.
As compared to TN or HER2+ subtypes, hormone
receptor positive HER2 negative (HR) tumors both have
less TIL and the tumors with LPBC do not show the
same improved survival benefit. Only 6 % of HR tumors
have LPBC and less than half have CD8+ T-cell infil-
trate (Fig. 1) [21]. The decreased lymphocytic infiltrate
may be due to the expression of the estrogen receptor
which has been shown to both promote a Th2 immune
environment and decrease MHC class II expression in
breast cancer cells [23, 24]. However, HR breast cancer
is the only breast cancer subtype where FOXP3+ infil-
trate predicts a worse survival [10, 21, 25]. In 148 HR+
tumors, increased FOXP3+ infiltrate was associated
with a decreased RFS (p = 0.006 HR 2.20 95 % CI 1.26–
3.85) and OS (p = 0.006, HR 2.57 95 % CI 1.31–5.60)
[10]. Potentially, a therapy that can effectively decrease
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FOXP3+ infiltrate may increase the magnitude of lympho-
cytic infiltrate in HR tumors and may improve clinical
response in the neoadjuvant setting (Table 2).
Immune checkpoint inhibitor therapy in breast cancer
PD-L1 expression has been associated with increased
TILs and better prognosis in breast cancer. In a study of
45 primary breast cancers, 89 % PD-L1+ and 24 % PD-L1-
breast cancers had moderate or diffuse TILs. Furthermore,
none of patients that had PD-L1+ breast cancer at diag-
nosis developed distant recurrence whereas 15 % of the
patients that had PD-L1- breast cancer at diagnosis did
develop distance recurrence [26]. PD-L1 infiltrate has
been associated with TN breast cancer and CD8+ T-cell
infiltrate (Table 2) [27]. These data suggest that PD-L1
expression is a marker of an immunologically active
breast cancer. Although increased TIL has also been
associated with increased PD-L1 infiltrate, the associ-
ation between increased TIL and response to immune
checkpoint therapy has not yet been established [28, 29].
Early trials of immune checkpoint inhibitor specific mono-
clonal antibodies have shown only modest clinical efficacy
in breast cancer. None of the breast cancer patients in-
cluded in the initial pembrolizumab (anti-PD-1) trial
showed any response to treatment and the combination
of tremelimumab (anti-CTLA4) and exemestane in HR
metastatic breast cancer demonstrated development of
stable disease as best response in 42 % of patients
[30, 31]. Several studies have shown a modest clinical
response in TN breast cancer to pembrolizumab and
Table 1 Effect on outcome of LPBC, CD8+, or FOXP3 tumor infiltrate by subtype
Breast cancer subtype
TN HR+ HER2+
Immune infiltrate DFS or RFS OS or DSS DFS or RFS OS or DSS DFS or RFS OS or DSS
LPBC +++ +++ ++ +
Elevated CD8+ + +++ + + (TBET)
Elevated FOXP3 - -
Abbreviations: DFS disease free survival, RFS relapse free survival, OS overall survival, DSS disease specific survival, LPBC lymphocyte predominant breast cancer,
TN triple negative, HR hormone receptor
+++ Increased (>2 sources); ++ (increased 2 sources) + Increased (one source); - Decreased (one source)
Fig. 1 Most breast cancers have evidence of lymphocytic infiltrates at the time of diagnosis, although the level of infiltrate is modest, and the
presence of CD8+ infiltrate varies between the breast cancer subtypes. The % individuals (x-axis) are shown for: a no evidence of TIL (white), TIL
<50 % (medium grey), and LBPC (black) data compiled from 6 studies. *Only one to two studies evaluated no infiltrate separately. b Presence of
CD8+ infiltrate (black) or no CD8+ infiltrate (white), data compiled from 3 studies
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atezolizumab (anti-PD-L1) inhibitor monotherapy, includ-
ing some complete responders. The Keynote 012 trial
reporting 27 patients with PD-L1 positive metastatic TN
breast cancer treated with pembrolizumab as a monother-
apy showed an overall response rate of 19 % with one
complete response and four partial responses as well as
26 % patients with stable disease [32]. Similar results have
been seen using anti-PD-L1 monoclonal antibodies. A trial
of 21 metastatic TN breast cancer patients treated with
atezolizumab monotherapy demonstrated a 19 % overall
response rate with two complete responses and two partial
responses [33]. Early data has further demonstrated that
combining chemotherapy and checkpoint inhibitor ther-
apy may increase the number of clinical responses to im-
mune checkpoint inhibitor therapy in TN breast cancer.
In a study of 24 metastatic TN breast cancer patients, the
combination of avelumab (anti-PD-L1) inhibitor and nab-
paclitaxel showed a response rate of 42 % (95 % CI 22.1 to
63.4 %) including a complete response rate of 4 %, partial
response rate of 67 %, and stable disease in 21 % of pa-
tients [34]. This data is promising, despite only 12 months
of follow up, that use of checkpoint inhibitors in com-
bination with chemotherapies may expand the number
of breast cancer patients that respond to immune check-
point inhibitor therapies particularly in TN breast cancer.
The number of patients with HER2+ and HR breast
cancer subtypes who respond to immune checkpoint in-
hibitor therapy is much lower. In one study of 27 HER2+
patients and 72 HR patients receiving avelumab therapy,
only 4 % of HER2+ and 3 % of HR patients demonstrated
a clinical response [35]. In one study of 25 PD-L1 positive
HR breast cancer patients treated with pembrolizumab, an
overall response rate of 12 % was observed and these were
only partial responses [36]. Newer immune checkpoint
therapies that activate the T-cell immune response rather
than block inhibition of T-cell activity including OX40
(CD134), OX40 ligand, and 41BB (CD137) may be able to
enhance immune-associated anti-tumor activity in breast
cancer. In pre-clinical mouse mammary tumor models,
treatment with either OX40 or 41BB monoclonal anti-
bodies were able to significantly decrease both tumor
growth and development of metastases [37–39]. Several
clinical trials using combination checkpoint therapy are
currently ongoing.
Augmenting immunity through conventional breast
cancer chemotherapy and monoclonal antibody therapy
A major mechanism of action of trastuzumab therapy in
HER2+ breast cancer may be immunologic. Monoclonal
antibodies can trigger antibody dependent cell mediated
cytotoxicity (ADCC) that results in the activation of NK
T-cells, macrophages, and dendritic cells. Activation of
cells of the innate immune system leads to the secretion
of Th1 cytokines, enhanced antigen processing, and pres-
entation of endogenous tumor antigens to T-cells eliciting
an adaptive immune response [40, 41]. Furthermore, the
enhanced HER2 specific immunity associated with trastu-
zumab therapy has been associated with improve clinical
prognosis. In a study of 87 locally advanced HER2 breast
cancer patients treated with trastuzumab, 94 % of the pa-
tients with high HER2 specific interferon gamma (IFN-g)
Th1 immunity had pCR as compared to 33 % of patients
that did not achieve pCR (p = 0.0002). In multivariate
analysis, a high HER2-specific Th1 immune response pre-
dicted whether a patient would develop pCR (OR 8.82
95 % CI 1.50 to 51.83 p = 0.016) [42]. In an adjuvant
chemotherapy trial of 95 HER2 breast cancer patients,
high HER2-specific Th1 immunity predicted improved
RFS (HR 16.9 95 % CI 3.9 to 71.4 p < 0.001) [43]. Both of
these studies found that trastuzumab was needed to stimu-
late increased Th1 HER2 specific immune responses as
patients not treated with trastuzumab did develop the
high Th1 HER2 specific immunity. Similarly in the FIN-
HER study of 209 HER2 breast cancer patients, only
patients that had been treated with trastuzumab had
improved distant DFS with each 10 % increase in TIL
(HR 0.82 95 % CI 0.58 to 1.16, p = 0.025 n = 94) [19].
For HER2+ breast cancer, the immunologic function of
trastuzumab to induce type 1 immunity appears to be
important for its therapeutic efficacy.
Cytotoxic chemotherapy has also been shown to increase
type 1 T-cell response. Some chemotherapeutic agents have
been shown to trigger immune recognition of the tumor
by induction of stress proteins released during cell death.
For example doxorubicin induces the secretion of a pro-
tein called high-mobility-group box 1 (HMGB1) from
dying cancer cells that binds to toll-like receptor (TLR)
4 on dendritic cells resulting in the secretion of IFN-g,
antigen presentation, and activation of T-cells [44]. Toll-
like receptors are highly conserved pattern recognition
receptors that activate the immune recognition and en-
hance pathogen presentation to the adaptive immune sys-
tem [45]. This resulting adaptive immune response may
be a major mechanism of response to doxorubicin therapy
because a TLR-4 genetic polymorphism, Asp299Gly, has
been shown to decrease the binding of HMGB1 and IFN-g
Table 2 Biomarker staining by IHC and prognosis in breast
cancer subtypes
Marker Measurement Good prognosis Breast cancer
subtype
CD8 Presence/absence Presence TN
PD-L1 >5 % membrane staining Presence TN
HER2 1+, 2+, 3+ 1+ HER2+
FOXP3 Low/High (above and
below median)
Low HR+
Abbreviations: TN triple negative, HR hormone receptor
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secretion by 50 % (p < 0.05) in in vitro assays. In an
evaluation of 280 breast cancer patients treated with
adjuvant doxorubicin, 40 % of the patients carrying the
TLR-4 Asp299Gly polymorphism developed metastatic
disease in 5 years as compared to 27 % of patients without
the polymorphism (RR 1.53 95 % CI 1.1 to 3.59 p = 0.03)
[44]. When comparing gene expression in 114 breast can-
cer patients that received anthracycline chemotherapy and
1062 breast cancer patients that did not receive chemo-
therapy, anthracycline therapy increased type 1 immune
response, and the increased CD8+ (HR 0.72 95 % CI 0.59
to 0.82 p = 0.005) and IFN-g (HR 0.56 95 % CI 0.56 to
0.89 p = 0.016) expression was associated with improved
pCR in patients that had been treated with anthracycline
[46]. Paclitaxel has also been shown to increase tumor
infiltrating type 1 T-cells by increasing the expression
of type 1 cytokines and decreasing Th2 CD4+ T-cells in
the tumor [47, 48]. Cyclophosphamide has been shown
to decrease Th2 regulatory T-cells without decreasing
circulating Th1 immune response at low doses [49].
Carboplatin and cisplatin have been shown to increase
MHC class 1 expression on the tumor while also de-
creasing intratumoral myeloid derived suppressor cells
and Th2 regulatory T-cells in the tumor [50]. Studies
are ongoing to determine the most effective way to
dose or sequence these agents to optimize their im-
munologic effects.
Newer options for immune modulation in breast cancer
therapy
Early clinical trials of metastatic breast cancer have dem-
onstrated that localized therapies, including radiation,
cryoablation, and cellular stress signals such as TLR ago-
nists, both induce local destruction of the tumor as well
as increase the systemic anti-tumor immune response
demonstrating clinical response in tumors distant from
the treated lesion. These distant responses occur because
the local cellular damage increases cellular stress signals
and trigger type 1 cytokine release, recruiting antigen pre-
senting cells to the tumor and improving antigen presen-
tation of tumor antigens to T-cells converting the tumor
an in situ vaccine [51, 52]. In a trial of 41 metastatic solid
tumor patients treated with radiation and concurrent ad-
juvant granulocyte-macrophage colony-stimulating factor,
11 of 41 patients (26.8 %, 95 % CI 14.2 to 49.9) had a 30 %
reduction in the volume of non-irradiated tumors. Five of
the 11 responding patients had breast cancer [53]. Simi-
larly, cryoablation of breast tumors has been shown to
increase type 1 cytokine secretion resulting in enhanced
presentation of tumor-specific antigens to T-cells inducing
a tumor-specific T-cell response [54, 55]. Cryoablation is
currently in clinical trials along with ipilimumab in breast
cancer and has shown both increase effector T-cell to
regulatory T-cell ratio and increase T-cell clonal expansion
in the tumor [56]. The TLR7 agonist imiquimod has been
shown to induce partial response in 20 % (95 % CI 3 to
56 %) of 10 breast cancer patients with skin metastases
that are typically unresponsive to therapy [57]. For tumors
with low immune infiltrate, local therapies can increase
the systemic T-cell response against the tumor and there-
fore increase the anti-tumor immune response to areas of
disease distant from the therapy.
Conclusion
With evidence that the magnitude and composition of
tumor immune infiltrate can affect prognosis and response
to therapy both for DCIS and invasive cancer, the pre-
therapy tumor immune environment can be used both as a
biomarker for the prognosis of an individuals’ disease as
well as a guide to determine what is the most appropriate
therapy. Currently, the International TILs Working Group
has started standardizing evaluation of breast cancer TILs
to be able to use this in clinical practice [58]. Standardizing
how to characterize a breast tumor by both the subtype
and immune environment (having high, intermediate, or
low immune infiltrate) will allow both the identification of
patients that may only need treatment with various emer-
ging immune therapies (including checkpoint inhibitor
therapy) and provide the optimal combinations and timing
of these powerful therapies to the patients with lower
immune infiltrate to allow a wider population of breast
cancer patients to benefit from targeted immune therapy.
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